Valvular Atrial Fibrillation (VAF) is a specific subtype of atrial fibrillation characterized by the presence of significant heart valve disease. In individuals with VAF, irregular and often rapid heartbeats occur due to abnormal electrical signals in the atria, the upper chambers of the heart. The presence of valvular heart disease, such as mitral stenosis or a mechanical heart valve, increases the risk of developing VAF. Managing VAF poses unique challenges, as treatment strategies need to consider both the atrial fibrillation and the underlying valvular pathology. Healthcare professionals typically tailor their approach based on factors like the severity of the valve disease, overall health status, and individual patient considerations. Close monitoring and a collaborative, multidisciplinary approach are essential in addressing the complexities of Valvular Atrial Fibrillation.
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain
Title : Innovative mechanisms, consequences and therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Comprehensive surgical revascularization for rapidly worsening ischemic heart failure
Deepak Puri, Max Healthcare, India